フォローフィードコミュニティでトレーダーや投資家とつながりましょう.
包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.
ターミナル モニターで株式と資産のウォッチリストを整理および監視します
CLARITIN(R) OTC Brand Sales Surpass $1 Billion Mark in U.S. The Success of CLARITIN Confirms Schering-Plough's Expertise in Prescription-to-OTC...
Head of Schering-Plough Global Communications Named 2004 Communicator of the Year KENILWORTH, N.J., Feb. 3 /PRNewswire-FirstCall/ -- Jeffrey A...
Head of Schering-Plough Research Institute Named One of Most Powerful Black Executives In Corporate America KENILWORTH, N.J., Jan. 20...
Standard & Poor's Announces Semi-Annual Reconstitution of Standard & Poor's/Barra Growth and Value Indices NEW YORK, Dec. 10 /PRNewswire/...
Schering-Plough CEO Calls on President Bush for Courage To Take Tough Actions In Reforming Health Care System Competing Pressures Must Be Overcome...
Schering-Plough Reports Comparative Pharmacokinetics and Pharmacodynamics Data for PEG-INTRON(R) and PEGASYS(R) in Hepatitis C...
PEG-INTRON(R) Studied in a Wide Range of Hepatitis C Patient Populations Researchers Present 44 Abstracts on PEG-INTRON at Annual Meeting Of...
Schering-Plough CEO Calls on Winner of Presidential Election to Adopt 4-Point Plan for Health Care Reform Effective Agenda Demands Sweeping Health...
Media Alert: Merck/Schering-Plough Pharmaceuticals to Conduct Call for Journalists Regarding U.S. Approval of VYTORIN WHITEHOUSE STATION, N.J. and...
Merck/Schering-Plough Pharmaceuticals to Conduct Conference Call and Webcast Regarding U.S. Approval of VYTORIN WHITEHOUSE STATION, N.J. and...
New Data on Schering-Plough Oncology Products to be Presented at ASCO 2004 Annual Meeting in New Orleans Researchers to Present 57 Abstracts on...
New Study Challenges Current Thinking About Varied Response to Hepatitis C Treatment in Different Racial Groups Study Reports Results in African...
Nation's Top Medical Centers Seek Participants for Largest Study Comparing Leading Hepatitis C Treatments Schering-Plough Sponsors IDEAL Study to...
Efficacy Data on PEG-INTRON(R) and REBETOL(R) in Wide Range of Hepatitis Patient Populations to Be Presented at Digestive Disease WEEK...
ご覧いただいた銘柄が下記のボックス内に表示されますので、過去閲覧した銘柄情報に簡単にアクセスすることができます。
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約
サインアップして広告なしのエクスペリエンスを体験してください
今すぐ試してください
広告を残す